Piśmiennictwo
1. Ford AC, Marwaha A, Sood R, et al. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a metaanalysis. Gut 2015;64:1049-57
2. Ford AC, Forman D, Bailey AG, et al. Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. Am J Gastroenterol 2007;102:957-65
3. Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology 2018;154:267-76
4. Bartnik W, Chojnacki J, Paradowski L i wsp. Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego. Gastroenterologia Kliniczna 2009;1:9-17
5. Wei-Yi Lei, Wei-Chuan Chang, Shu-Hui Wen, et al. Impact of concomitant dyspepsia and irritable bowel syndrome on symptom burden in patients with gastroesophageal reflux disease. Journal of the Formosan Medical Assotiation 2019;118:797-806
6. Yarandi SS, Christie J. Functional dyspepsia in review: pathophysiology and challenges in the diagnosis and management due to coexisting gastroesophageal reflux disease and irritable bowel syndrome. Gastroenterol Res Pract 2013;2013:351086
7. Mulak A. Rola mikroflory w regulacji osi mózgowo-jelitowej. Gastroenterol Prakt 2014;6(4):48-54
8. Talley NJ, Ford AC. Functional dyspepsia. N Engl J Med 2015;373(19):1853-63
9. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132(3):913-20
10. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut 2017;66:6-30
11. Konturek S. Fizjologia układu pokarmowego. Wydanie II. Warszawa: PZWL, 2013
12. Tack J, Pandolfino JE. Pathophysiology of gastroesophageal reflux disease. Gastroenterology 2018;154:277-88
13. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol 2008;8:690-6
14. Mushiroda T, Takahara E, Nagata O. The involvement of flavin containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastrokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab Dispos 2000;28:1231-37
15. Tonini M, Cipollina L, Poluzzi E, et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004;19:379-90
16. Pradeep Kumar BT, Mamatha KR, Nagesh NS, et al. A comparative prospective study to assess the clinical efficacy and safety of pantoprazole monotherapy versus pantoprazole and itopride dual therapy in patients with gastroesophageal reflux disease in a tertiary care hospital. Int J Basic Clin Pharmacol 2016;5(5):1953-7
17. Chen Lixia, Bai Banjun, Song Xinling, et al. Clinical curative effect observation and nursing experience of treatment of Gastroesophageal reflux disease with esomeprazole combined with itopride. Acta Medica Mediterranea 2016;32:1173
18. Ezzat WF, Fawaz SA, Fathey H, et al. Virtue of Adding Prokinetics to Proton Pump Inhibitors in the Treatment of Laryngopharyngeal Reflux Disease: Prospective Study. J Otolaryngol Head Neck Surg 2011;40(4):350-6
19. Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: management of dyspepsia. American Journal of Gastroenterology 2017;112:988-1013
20. Tsubouchi T, Saito T, Mizutani F, et al. Stimulatory action of itopride hydrochloride on colonic motor activity in vitro and in vivo. J Pharmacol Exp Ther 2003;306:787-93
21. Gasiorowska A, Poh CH, Fass R. Gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS) – is it one disease or an overlap of two disorders? Dig Dis Sci 2009;54:1829-34